Treatment of rheumatic diseases and hepatitis B virus coinfection

被引:0
作者
Anna Felis-Giemza
Marzena Olesińska
Katarzyna Świerkocka
Ewa Więsik-Szewczyk
Ewa Haładyj
机构
[1] Institute of Rheumatology,
[2] Connective Tissue Department,undefined
来源
Rheumatology International | 2015年 / 35卷
关键词
Rituximab; Tocilizumab; Abatacept; Biological therapy; Hepatitis B; Rheumatic diseases;
D O I
暂无
中图分类号
学科分类号
摘要
We often encounter rheumatological patients coinfected with hepatitis B in daily practice. In this paper, we will discuss the basic characteristics of the virus of hepatitis B, course of infection, the safety of rituximab, tocilizumab, abatacept treatment and therapeutic recommendations in management of patients with rheumatic diseases.
引用
收藏
页码:385 / 392
页数:7
相关论文
共 315 条
[1]  
Juszczyk J(2000)Clinical course and consequences of hepatitis B infection Vaccine 18 S23-S25
[2]  
Tiollais P(1981)Biology of hepatitis B virus Science 213 406-411
[3]  
Charnay P(2001)Nomenclature for antiviral resistant of human hepatitis B virus mutations in the polymerase region Hepatology 33 751-757
[4]  
Vyas GN(2008)Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future Rev Med Virol 18 19-34
[5]  
Stuyver LJ(2009)Diagnosis and treatment of chronic hepatitis B: 2009 update Minerva Gastroenterol Dietol 55 5-22
[6]  
Locarnini SA(2007)Natural history of hepatitis B virus infection: an update for clinicians Mayo Clin Proc 82 967-975
[7]  
Lok A(2011)Let the fog be lifted: screening for hepatitis B virus before biological therapy Ann Rheum Dis 70 1701-1703
[8]  
Richman DD(2010)Pathogenesis of hepatitis B virus infection Pathol Biol (Paris) 58 258-266
[9]  
Carman WF(2009)Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection Hepatology 50 1773-1782
[10]  
Dienstag JL(2007)Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA J Virol 81 7351-7362